p16 inactivation in pancreatic intraepithelial neoplasias (PanINs) arising in patients with chronic pancreatitis

被引:88
作者
Rosty, C
Geradts, J
Sato, N
Wilentz, RE
Roberts, H
Sohn, T
Cameron, JL
Yeo, CJ
Hruban, RH
Goggins, M
机构
[1] Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA
[2] Johns Hopkins Med Inst, Dept Oncol, Baltimore, MD 21205 USA
[3] Johns Hopkins Med Inst, Dept Surg, Baltimore, MD 21205 USA
[4] Johns Hopkins Med Inst, Dept Med, Baltimore, MD 21205 USA
[5] Roswell Pk Canc Inst, Dept Pathol & Lab Med, Buffalo, NY 14263 USA
[6] Univ Oxford, Nuffield Dept Clin Lab Sci, Oxford OX1 2JD, England
[7] Inst Curie, Dept Pathol, Paris, France
关键词
chronic pancreatitis; PanIN; p16; Smad4;
D O I
10.1097/00000478-200312000-00001
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Patients with long-standing chronic pancreatitis are thought to be at increased risk of developing pancreatic ductal adenocarcinoma, but the mechanism for this increased risk is unknown. Since increasing evidence supports the notion that infiltrating pancreatic ductal adenocarcinomas arise from pancreatic intraepithelial lesions (PanINs), we sought to determine if patients with chronic pancreatitis harbor PanINs with alterations in tumor suppressor genes that are associated with infiltrating pancreatic ductal adenocarcinoma. We identified 122 patients with a diagnosis of chronic pancreatitis and 29 patients with a well-differentiated pancreatic endocrine tumor that underwent pancreatic surgery at the Johns Hopkins Hospital from 1985 to 1999. PanINs from each resection specimen were identified, graded, counted, and correlated with smoking and alcohol history. The expression patterns of p 16 and Smad4 were determined in a subset of PanINs by immunohistochemistry, and the pattern of labeling compared with that seen in PanINs associated with infiltrating adenocarcinoma of the pancreas as identified in prior studies, and to PanfNs associated with pancreatic endocrine tumor. Duct lesions were present in 80 of the 122 pancreata with chronic pancreatitis (66%). Of 405 duct lesions identified in the chronic pancreatitis group, 7.6% were reactive changes, 65.5% were PanIN-1A, 18% werePanIN-1B, 7.4%were PanIN-2,and 1.5% were PanIN-3. Within the pancreatic endocrine tumor group, 22 PanfNs were identified: 15 PanIN-1A, 4 PanIN-1B, and 3 PanIN-2. There were significantly fewer high-grade PanfNs in the pancreata with chronic pancreatitis than in pancreata with pancreatic adenocarcinoma (P < 0.0001). Within the chronic pancreatitis group, the 80 patients with PanINs were significantly older than the 42 patients without PanfNs (mean age 57.0 +/- 14.1 years vs. 50.9 +/- 14.7 years, P = 0.01). Smoking history was not associated with PanIN prevalence or grade, but patients who reported a history of excessive alcohol consumption had fewer PanINs (25 of 44 harbored PanINs, 57%) than those who did not (54 of 74, 73%, P = 0.07). In the chronic pancreatitis group, 0% of PanIN-1A, 11% of the PanIN-1B, 16% of the PanIN-2, and 40% of the PanIN-3 lesions showed loss of p16 expression, whereas all of the PanINs from patients with an pancreatic endocrine tumor retained p16 expression. All of the PanINs analyzed from patients with chronic pancreatitis retained normal Smad4 expression. We conclude that a significant minority of PanINs arising in patients with chronic pancreatitis show loss of p16 expression. This alteration, common to pancreatic cancer-associated PanINs, may contribute to the predisposition of patients with chronic pancreatitis to develop pancreatic ductal adenocarcinoma.
引用
收藏
页码:1495 / 1501
页数:7
相关论文
共 29 条
[1]  
Berger DH, 1999, CANCER, V85, P326, DOI 10.1002/(SICI)1097-0142(19990115)85:2<326::AID-CNCR9>3.0.CO
[2]  
2-O
[3]   Immunohistochemical evaluation of HER-2/neu expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasms [J].
Day, JD ;
Digiuseppe, JA ;
Yeo, C ;
LaiGoldman, M ;
Anderson, SM ;
Goodman, SN ;
Kern, SE ;
Hruban, RH .
HUMAN PATHOLOGY, 1996, 27 (02) :119-124
[4]   Aberrant methylation of preproenkephalin and p16 genes in pancreatic Intraepithelial neoplasia and pancreatic ductal adenocarcinoma [J].
Fukushima, N ;
Sato, N ;
Ueki, T ;
Rosty, C ;
Walter, KM ;
Wilentz, RE ;
Yeo, CJ ;
Hruban, RH ;
Goggins, M .
AMERICAN JOURNAL OF PATHOLOGY, 2002, 160 (05) :1573-1581
[5]   Immunohistochemical p16INK4a analysis of archival tumors with deletion, hypermethylation, or mutation of the CDKN2/MTS1 gene -: A comparison of four commercial antibodies [J].
Geradts, J ;
Hruban, RH ;
Schutte, M ;
Kern, SE ;
Maynard, R .
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2000, 8 (01) :71-79
[6]   p16INK4a alterations in chronic pancreatitis-indicator for high-risk lesions for pancreatic cancer [J].
Gerdes, B ;
Ramaswamy, A ;
Kersting, M ;
Ernst, M ;
Lang, S ;
Schuermann, M ;
Wild, A ;
Bartsch, DK .
SURGERY, 2001, 129 (04) :490-497
[7]   BRCA2 is inactivated late in the development of pancreatic intraepithelial neoplasia -: Evidence and implications [J].
Goggins, M ;
Hruban, RH ;
Kern, SE .
AMERICAN JOURNAL OF PATHOLOGY, 2000, 156 (05) :1767-1771
[8]   Pancreatic intraepithelial neoplasia -: A new nomenclature and classification system for pancreatic duct lesions [J].
Hruban, RH ;
Adsay, NV ;
Albores-Saavedra, J ;
Compton, C ;
Garrett, ES ;
Goodman, SN ;
Kern, SE ;
Klimstra, DS ;
Klöppel, G ;
Longnecker, DS ;
Lüttges, J ;
Offerhaus, GJA .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2001, 25 (05) :579-586
[9]   Aberrant methylation of the 5′ CpG island of TSLC1 is common in pancreatic ductal adenocarcinoma and is first manifest in high-grade PanINs [J].
Jansen, M ;
Fukushima, N ;
Rosty, C ;
Walter, K ;
Altink, R ;
van Heek, T ;
Hruban, R ;
Offerhaus, JG ;
Goggins, M .
CANCER BIOLOGY & THERAPY, 2002, 1 (03) :293-296
[10]   Hereditary pancreatitis and the risk of pancreatic cancer [J].
Lowenfels, AB ;
Maisonneuve, P ;
DiMagno, EP ;
Elitsur, Y ;
Gates, LK ;
Perrault, J ;
Whitcomb, DC ;
Aranha, G ;
Banks, P ;
Burton, FR ;
CarrLocke, D ;
Dyck, WP ;
Gish, RG ;
Goodale, RL ;
Lehman, G ;
Martin, SP ;
Potts, J ;
Sherman, S ;
Ulrich, CD ;
Yakshe, P ;
Yeaton, P ;
Hamanaka, Y ;
Koizumi, M ;
Tomioka, T ;
Tsunoda, T ;
Yamadera, K ;
Delmont, JP ;
Beger, HG ;
Holstege, A ;
Keim, V ;
Layer, P ;
Triantafillidis, J ;
Boyle, P ;
Cavallini, G ;
Gullo, L ;
Pedrazzoli, S ;
Uomo, G ;
Castano, DGL ;
Ihse, I ;
Buchler, M ;
Elias, E .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1997, 89 (06) :442-446